Clinic visits and prescribing patterns among veterans affairs maryland health care system dementia patients
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Our objective was to determine how patient demographics and outpatient referrals to specialized dementia (DEM) or mental health (MH) clinics influence receipt of anti-dementia (AD), antidepressant (ADEP), antipsychotic (APSY) and sedative-hypnotic (SEDH) medications among veterans with dementia.
Retrospective, cross-sectional observational study.
Veterans Affairs Maryland Health Care System (VAMHCS).
Veterans aged ≥ 60 years with Alzheimer's or related dementia diagnosis after 1999 with minimum of one-year follow-up or death were included.
Retrospective analysis of VAMHCS electronic medical records were used to determine predictors of AD, ADEP, APSY, and SEDH prescribing using logistic regression models that examined visits to DEM or MH clinics, patient age, follow-up time, race/ethnicity and marital status.
Among 1209 veterans with average follow-up of 3.2 (SD 1.9) years, 36% percent had MH visits, 38% had DEM visits and 19% visited both clinics. DEM visits were associated with AD and ADEP but not APSY medication receipt (OR(AD:DEM) = 1.47, 95% CI = (1.052, 2.051); OR(ADEP:DEM) = 1.66, 95% CI = (1.193, 2.302); OR(APSY:DEM) = 1.35, 95% CI = (0.941, 1.929)). MH visit was associated with ADEP and APSY medication receipt (OR(AD:MH)/ = 1.16, 95% CI = (0.821, 1.631); OR(ADEP:MH) = 2.83, 95% CI = (2.005, 4.005); OR (APSY:MH) = 4.41, 95% CI = (3.109, 6.255)).
In the VAMHCS dementia population, visits to DEM or MH specialty clinics increase the odds of receiving AD, ADEP, and APSY medications.
- Grossberg GT. Diagnosis and treatment of Alzheimer's disease. J Clin Psychiatry. 2003;64Suppl 9:3–6.
- Grossberg GT, Desai AK. Management of Alzheimer's disease. J Gerontol A Biol Sci Med Sci. Apr 2003;58(4):331–353.
- 2009 Alzheimer's Disease Facts and Figures. http://www.alz.org
- Boustani M, Peterson B, Hanson L, Harris R, Lohr KN. Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. Jun 3 2003;138(11):927–937.
- Holsinger T, Deveau J, Boustani M, Williams JW, Jr. Does this patient have dementia? Jama. Jun 6 2007;297(21):2391–2404. CrossRef
- Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. Jul 2007;3(3):186–191. CrossRef
- Rice DP, Fillit HM, Max W, Knopman DS, Lloyd JR, Duttagupta S. Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. Am J Manag Care. Aug 2001;7(8):809–818.
- Malone DC, McLaughlin TP, Wahl PM, et al. Burden of Alzheimer's disease and association with negative health outcomes. Am JManag Care. Aug 2009;15(8):481–488.
- Hill JW, Futterman R, Duttagupta S, Mastey V, Lloyd JR, Fillit H. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare. Neurology. Jan 8 2002;58(1):62–70.
- Fillit H, Hill JW, Futterman R. Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy. Fam Med. Jul–Aug 2002;34(7):528–535.
- Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. May 8 2001;56(9):1154–1166.
- Pomara N, Ott BR, Peskind E, Resnick EM. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. Alzheimer Dis Assoc Disord. Jan–Mar 2007;21(1):60–64. CrossRef
- Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. Mar 4 2008;148(5):379–397.
- Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med. Nov 25 1999;341(22):1670–1679. CrossRef
- Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderateto-severe Alzheimer's disease. N Engl J Med. Apr 3 2003;348(14):1333–1341. CrossRef
- Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Jama. Oct 19 2005;294(15):1934–1943. CrossRef
- Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. Oct 12 2006;355(15):1525–1538. CrossRef
- Mitchell AJ. Depression as a risk factor for later dementia: a robust relationship? Age Ageing. May 2005;34(3):207–209. CrossRef
- Pfennig A, Littmann E, Bauer M. Neurocognitive impairment and dementia in mood disorders. J Neuropsychiatry Clin Neurosci. Fall 2007;19(4):373–382.
- Kohn R, Epstein-Lubow G. Course and outcomes of depression in the elderly. Curr Psychiatry Rep. Feb 2006;8(1):34–40. CrossRef
- Kaup BA, Loreck D, Gruber-Baldini AL, et al. Depression and its relationship to function and medical status, by dementia status, in nursing home admissions. Am J Geriatr Psychiatry. May 2007;15(5):438–442. CrossRef
- Hargrave R, Reed B, Mungas D. Depressive syndromes and functional disability in dementia. J Geriatr Psychiatry Neurol. Summer 2000;13(2):72–77. CrossRef
- Chronic Condition Data Warehouse, User Manual. http://www.resdac.umn.edu/CCW/data_available.asp. Accessed October 1, 2009.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. Jul 1984;34(7):939–944.
- Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. May 8 2001;56(9):1143–1153.
- Pressley JC, Trott C, Tang M, Durkin M, Stern Y. Dementia in community-dwelling elderly patients: A comparison of survey data, medicare claims, cognitive screening, reported symptoms, and activity limitations. J Clin Epidemiol. Sep 2003;56(9):896–905. CrossRef
- Taylor DH, Jr., Fillenbaum GG, Ezell ME. The accuracy of medicare claims data in identifying Alzheimer's disease. J Clin Epidemiol. Sep 2002;55(9):929–937. CrossRef
- Newcomer R, Clay T, Luxenberg JS, Miller RH. Misclassification and selection bias when identifying Alzheimer's disease solely from Medicare claims records. J Am Geriatr Soc. Feb 1999;47(2):215–219.
- Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci. Oct 2008;9(10):768–778. CrossRef
- Bertram L, Lange C, Mullin K, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet. Nov 2008;83(5):623–632. CrossRef
- Bertram L, Tanzi RE. Of replications and refutations: the status of Alzheimer's disease genetic research. Curr Neurol Neurosci Rep. Sep 2001;1(5):442–450. CrossRef
- Zuckerman IH, Ryder PT, Simoni-Wastila L, et al. Racial and ethnic disparities in the treatment of dementia among Medicare beneficiaries. J Gerontol B Psychol Sci Soc Sci. Sep 2008;63(5):S328–333.
- Mehta KM, Yin M, Resendez C, Yaffe K. Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease. Neurology. Jul 12 2005;65(1):159–162. CrossRef
- Lerner AJ, McClendon MJ, Sami SA, Ogrocki PK, Adams KB, Smyth KA. Factors affecting usage patterns of memantine in Alzheimer disease. Alzheimer Dis Assoc Disord. Apr–Jun 2008;22(2):137–143. CrossRef
- Froehlich TE, Bogardus ST, Jr., Inouye SK. Dementia and race: are there differences between African Americans and Caucasians? J Am Geriatr Soc. Apr 2001;49(4):477–484. CrossRef
- Johnson KS, Elbert-Avila KI, Tulsky JA. The influence of spiritual beliefs and practices on the treatment preferences of African Americans: a review of the literature. J Am Geriatr Soc. Apr 2005;53(4):711–719. CrossRef
- Roberts JS, Connell CM, Cisewski D, Hipps YG, Demissie S, Green RC. Differences between African Americans and whites in their perceptions of Alzheimer disease. Alzheimer Dis Assoc Disord. Jan–Mar 2003;17(1):19–26. CrossRef
- Hillmer M, Krahn M, Hillmer M, Pariser P, Naglie G. Prescribing patterns for Alzheimer disease: survey of Canadian family physicians. Can Fam Physician. Feb 2006;52:208–209.
- Ruof J, Mittendorf T, Pirk O, von der Schulenburg JM. Diffusion of innovations: treatment of Alzheimer's disease in Germany. Health Policy. Apr 2002;60(1):59–66. CrossRef
- Shen Y, Hendricks A, Li D, Gardner J, Kazis L. VA-Medicare dual beneficiaries’ enrollment in Medicare HMOs: access to VA, availability of HMOs, and favorable selection. Med Care Res Rev. Aug 2005;62(4):479–495. CrossRef
- Shen Y, Hendricks A, Zhang S, Kazis LE. VHA enrollees’ health care coverage and use of care. Med Care Res Rev. Jun 2003;60(2):253–267. CrossRef
- Borowsky SJ, Cowper DC. Dual use of VA and non-VA primary care. J Gen Intern Med. May 1999;14(5):274–280. CrossRef
- Clinic visits and prescribing patterns among veterans affairs maryland health care system dementia patients
The journal of nutrition, health & aging
Volume 14, Issue 8 , pp 677-683
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Alzheimer's disease
- Veterans Affairs Health Care System
- Electronic Medical Record
- Industry Sectors
- Author Affiliations
- 1. Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, USA
- 2. Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, USA
- 3. Veterans Affairs Maryland Health Care System, Baltimore, MD, USA